Waters Corporation

https://www.waters.com

Waters Corporation is an American company headquartered in Milford, Massachusetts, that specializes in providing analytical instruments, software, and services. Its core business revolves around chromatography, mass spectrometry, laboratory informatics, and rheometry. The company's mission is centered on customer success, aiming to create business advantages for laboratory-dependent organizations through sustainable scientific innovation, thereby advancing areas such as healthcare delivery, environmental management, food safety, water quality, consumer products, and high-value chemicals.

Waters Corporation offers a comprehensive portfolio of products, including ACQUITY UPLC Systems, Xevo mass spectrometry systems, Alliance HPLC systems, and Empower chromatography software. Additionally, its TA Instruments division provides thermal analysis and rheometry instruments. These technologies serve diverse market segments, including life sciences, materials science, food and beverage, environmental analysis, biopharma, chemical, clinical research, diagnostics, and forensics.

Led by President and CEO Udit Batra, who was appointed in September 2020, Waters Corporation recently completed a significant merger on February 9, 2026, with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company. This strategic move aims to establish Waters as a global leader in life sciences and diagnostics. The company has also introduced new products, such as the ARES-G3 Rheometer in March 2026 and the omniDAWN Multi-Angle Light Scattering (MALS) Photometer in April 2026, and announced FDA clearance for an at-home cervical cancer screening tool in April 2026. Waters' analytical instruments are widely regarded as a gold standard in various applications, particularly in biopharmaceutical LC-MS.

Latest updates

Waters Gains CE Mark for BD BACTEC FXI, Bolstering Clinical Diagnostics Portfolio

Event summary

  • Waters Corporation received CE marking for the BD BACTEC FXI Culture System, enabling commercialization in Europe.
  • The new system reduces time to pathogen detection by approximately 3 hours (~15%) compared to the previous generation.
  • A key innovation is automated blood volume measurement, addressing a common source of diagnostic error (up to 85% of vials improperly filled).
  • The system features a capacity of up to 960 vials per module, designed for high-throughput microbiology labs.

The big picture

The acquisition of BD Biosciences and Diagnostic Solutions by Waters signals a strategic shift towards expanding its presence in the high-growth clinical diagnostics market. The BD BACTEC FXI system addresses a critical need for faster and more accurate sepsis diagnostics, a market driven by increasing mortality rates and the imperative for antimicrobial stewardship. This move positions Waters to capitalize on the rising demand for automated, high-throughput testing solutions within the broader life sciences sector.

What we're watching

Market Adoption
The speed of adoption in Europe will depend on lab infrastructure upgrades and reimbursement policies, potentially limiting initial revenue gains despite regulatory clearance.
Regulatory Expansion
Success in securing approvals in other key global markets, particularly the US, will be crucial for realizing the full potential of the BD BACTEC FXI system.
Competitive Landscape
How Waters and BD manage the transition of manufacturing and regulatory responsibilities will impact the system's reliability and Waters' ability to compete with established players in clinical microbiology.

Waters Expands Biopharma Analytics with Extended-Range MALS Detector

Event summary

  • Waters launched the omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, an extended-range detector for UHPLC/UPLC workflows.
  • The new detector extends UPLC-compatible sizing ten-fold, from 50 to 500 nm in radius.
  • The omniDAWN Photometer reportedly delivers up to 4x faster chromatographic run times and reduces sample consumption by 30-50%.
  • The platform integrates with Waters UPLC Systems and columns and is powered by ASTRA™ Software, compatible with Empower™ Software.

The big picture

The launch addresses a growing need for advanced analytical capabilities in the biopharmaceutical sector, particularly as complex therapies like ADCs, LNPs, and viral vectors advance through development and quality control. This represents a strategic move by Waters to maintain its position in a market increasingly demanding faster, more efficient, and higher-resolution analytical workflows, potentially impacting competitors offering similar solutions. The timing aligns with the broader trend of increasing regulatory scrutiny and demand for robust characterization data for novel therapeutics.

What we're watching

Adoption Rate
The speed at which laboratories adopt the omniDAWN Photometer will depend on the demonstrated ROI versus existing solutions, particularly given the cost of upgrading instrumentation.
Regulatory Impact
Increased throughput and reduced sample consumption could accelerate regulatory review timelines for biologics, potentially creating a competitive advantage for Waters' customers.
Software Integration
The successful integration of ASTRA and Empower software, and the ease of use for users, will be critical for widespread adoption and realizing the full benefits of the new detector.

Waters Acquires BD Diagnostics, Secures At-Home Cervical Cancer Screening Lead

Event summary

  • Waters Corporation (WAT) has completed the acquisition of BD Biosciences and BD Diagnostic Solutions from Becton, Dickinson and Company.
  • The FDA has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay for at-home use, expanding access to cervical cancer screening.
  • The BD Onclarity HPV Assay is the most comprehensive HPV screening tool in the U.S., detecting six individual and three pooled HPV genotypes.
  • The kit utilizes the fully automated BD COR™ System for sample processing and analysis.
  • Waters is establishing partnerships to broaden access to the self-collection kit, expected to be available by prescription in the coming months and covered by major insurance providers.

The big picture

This acquisition positions Waters as a significant player in the rapidly expanding at-home diagnostics market, addressing a critical need for improved cervical cancer screening access. The FDA clearance validates the efficacy of the self-collection method, which has been identified as a key strategy to address the 60% of unscreened or under-screened individuals. The deal represents a strategic shift for Waters, expanding its portfolio beyond analytical technologies into direct patient care solutions.

What we're watching

Integration Risk
The success of Waters’ acquisition hinges on the seamless integration of BD’s diagnostics businesses, which could face operational and cultural challenges.
Adoption Rate
The pace at which healthcare providers and patients adopt the at-home self-collection kit will determine the financial impact on Waters and its ability to significantly reduce cervical cancer screening gaps.
Reimbursement
Continued coverage by private insurance, Medicaid, and Medicare will be crucial for sustained demand and market penetration of the Onclarity kit.

Waters Secures $3.5 Billion in Debt to Repay Augusta Term Loan

Event summary

  • Waters Corporation issued $3.5 billion in senior notes across five tranches due 2027, 2029, 2031, 2033, and 2036.
  • The notes are being issued by Waters' subsidiary, Augusta SpinCo Corporation.
  • Proceeds will be used to repay a $3.5 billion delayed draw term loan taken out by Augusta in February 2026.
  • Barclays, Citigroup, J.P. Morgan, BofA Securities, and HSBC are acting as bookrunners for the offering.

The big picture

This substantial debt offering highlights Waters' strategic decision to restructure Augusta’s financing. The delayed draw term loan likely facilitated a specific acquisition or investment, and the subsequent repayment demonstrates a commitment to managing leverage. The size of the offering underscores the significant capital involved in Waters' strategic initiatives and the company’s reliance on debt markets to fund growth.

What we're watching

Debt Structure
The staggered maturity dates suggest a desire to manage refinancing risk, but also indicate a potentially higher overall cost of capital compared to a single, longer-dated issuance.
Augusta Performance
Augusta's performance will be critical, as its ability to service the debt is directly tied to Waters' financial stability and credit rating.
Interest Rate Risk
The fixed interest rates on the notes expose Waters to potential losses if interest rates decline significantly, though this is somewhat mitigated by the staggered maturities.

Waters Rheometer Upgrade Accelerates Materials Science Research

Event summary

  • Waters Corporation launched the ARES-G3 Rheometer, a next-generation instrument for materials research and development.
  • The ARES-G3 Rheometer captures up to 25,000 data points per second, a 10x increase over its predecessor.
  • Standard testing times are reduced by up to 80% through the integration of Fast Frequency Chirps.
  • The new rheometer retains compatibility with existing ARES-G2 methods and fixtures.
  • Chris Macosko, Professor Emeritus at the University of Minnesota, highlighted the instrument’s ability to capture previously inaccessible data on fast-changing materials.

The big picture

The ARES-G3 launch underscores the growing demand for faster, more precise materials characterization in industries like polymers, composites, and coatings. This trend is driven by the need for accelerated product development cycles and a deeper understanding of material behavior at a molecular level. Waters' investment in this technology positions them to capitalize on this demand, but also increases pressure to continually innovate and maintain a technological lead.

What we're watching

Adoption Rate
The speed of adoption among existing ARES-G2 users will be a key indicator of the ARES-G3's success, particularly given the backwards compatibility.
Competitive Response
Competitors in the analytical instrumentation space will likely respond with their own advancements, potentially triggering a price war or a new wave of innovation.
Workflow Impact
The claimed labor savings (hundreds of workdays per year) will need to be validated by customers, as this represents a significant value proposition.

Waters Rheometer Upgrade Accelerates Materials Science Research

Event summary

  • Waters Corporation launched the ARES-G3 Rheometer, a next-generation instrument for materials research and development.
  • The ARES-G3 Rheometer captures up to 25,000 data points per second, a 10x increase over its predecessor.
  • Standard testing times are reduced by up to 80% through integrated Fast Frequency Chirps.
  • The new rheometer retains compatibility with existing ARES-G2 methods and fixtures.
  • Chris Macosko, Professor Emeritus at the University of Minnesota, highlighted the instrument’s ability to capture previously inaccessible data on rapidly changing materials.

The big picture

The ARES-G3 launch underscores the increasing demand for faster, higher-resolution data in materials science, driven by the need for accelerated product development cycles and deeper understanding of complex material behavior. This capability is particularly valuable in sectors like polymer and composites development, where iterative testing is crucial. Waters’ focus on integrating software and hardware solutions, as seen with the TRIOS software, reflects a broader trend towards more holistic analytical instrument offerings.

What we're watching

Adoption Rate
The speed of adoption among existing ARES-G2 users will indicate the perceived value and ease of integration of the new features.
Competitive Response
Competitors in the rheometry market will likely respond with their own advancements, potentially creating pricing pressure or accelerating the pace of innovation.
Workflow Impact
The actual impact on lab workflows and the realization of the claimed hundreds of workdays saved per year will be a key indicator of the ARES-G3’s ROI for customers.

Waters CEO to Address TD Cowen Healthcare Conference

Event summary

  • Waters Corporation CEO Udit Batra will participate in a fireside chat at the TD Cowen Health Care Conference.
  • The event will be held on March 2nd, 2026, at 11:10 AM Eastern Time.
  • A live webcast will be available on the Waters Investor Relations website.
  • A replay of the webcast will be accessible for 90 days.

The big picture

Waters' participation in the TD Cowen conference underscores the importance of investor communication in the capital markets. The company’s focus on high-volume testing environments positions it to benefit from ongoing trends in personalized medicine and public health monitoring, but also exposes it to regulatory changes and pricing pressures within the diagnostics sector. The fireside chat offers a window into Waters’ strategy for navigating these challenges and capitalizing on opportunities.

What we're watching

Strategic Outlook
The fireside chat provides an opportunity for management to signal shifts in Waters’ strategic priorities, particularly given the evolving landscape of regulated testing environments.
Growth Drivers
How Waters addresses the increasing demand for advanced analytical technologies in areas like disease detection and antibiotic resistance will be a key indicator of future growth.
Investor Sentiment
The market's reaction to Batra’s commentary will reveal the degree to which investors believe Waters can sustain its position as a leader in the life sciences and diagnostics space.

Waters Introduces Microflow LC Columns for Sensitive Bioseparations

Event summary

  • Waters launched 1 mm I.D. liquid chromatography (LC) columns with MaxPeak Premier Technology on February 17, 2026.
  • The new columns offer up to 2x higher sensitivity compared to stainless steel microflow columns.
  • They reduce sample usage by up to 75% and solvent consumption by up to 4x compared to 2.1 mm I.D. columns.
  • The technology applies Waters’ MaxPeak High Performance Surface (HPS) Technology to minimize nonspecific adsorption.

The big picture

The launch underscores the growing demand for analytical techniques that maximize throughput while minimizing resource consumption, a trend driven by the rising complexity of biopharmaceutical research and the increasing focus on sustainability in laboratory practices. The move to microflow technology represents a significant shift in analytical chemistry, allowing for deeper insights with limited sample availability, a critical factor in emerging fields like cell and gene therapy. Waters’ investment in this area positions them to capitalize on the expanding market for advanced analytical solutions within the life sciences sector.

What we're watching

Adoption Rate
The speed at which laboratories adopt these microflow columns will depend on the cost-benefit analysis relative to existing workflows, particularly in regulated environments.
Competitive Response
Competitors in the chromatography space will likely respond with their own advancements in microflow technology, potentially intensifying pricing pressure and accelerating innovation cycles.
Application Expansion
The extent to which the columns’ benefits are realized across diverse applications beyond the initially targeted areas (bioseparations, DMPK, 'omics) will determine the long-term market penetration.

Waters Acquires BD Biosciences & Diagnostics in $11.8 Billion Deal

Event summary

  • Waters Corporation completed its acquisition of BD's Biosciences & Diagnostic Solutions businesses via a Reverse Morris Trust transaction.
  • The deal, valued at approximately $11.8 billion, results in a combined entity positioned as a global leader in life sciences and diagnostics.
  • Waters shareholders own 60.8% of the combined company, while BD shareholders own 39.2%.
  • Claire M. Fraser, Ph.D., a renowned genome scientist, has been appointed to Waters' Board of Directors.
  • The combined company has reorganized into four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences.

The big picture

The acquisition represents a significant consolidation within the life sciences and diagnostics sector, creating a formidable competitor with expanded capabilities. By combining Waters’ analytical expertise with BD’s diagnostics portfolio, the company aims to capitalize on the growing demand for high-volume, regulated testing, particularly in areas like personalized medicine and infectious disease diagnostics. The Reverse Morris Trust structure suggests a strategic desire to avoid significant regulatory hurdles, but the integration of two large organizations will present considerable operational challenges.

What we're watching

Integration Risk
The success of the combination hinges on Waters’ ability to effectively integrate BD’s Biosciences & Diagnostic Solutions businesses, a complex undertaking given the different organizational cultures and product portfolios.
Regulatory Scrutiny
Given the size and scope of the combined entity, Waters will likely face increased regulatory scrutiny, potentially impacting the speed and ease with which it can introduce new products and expand into new markets.
Growth Trajectory
The company’s stated focus on high-volume testing in regulated applications will be a key indicator of success; the pace at which Waters can leverage the combined assets to achieve this will determine long-term value creation.

Waters CEO to Address J.P. Morgan Healthcare Conference

Event summary

  • Waters Corporation CEO Udit Batra will present at the 44th Annual J.P. Morgan Healthcare Conference.
  • The presentation is scheduled for January 12, 2026, at 2:15 PM Pacific Time.
  • A live webcast will be available on the Waters Investor Relations website, with a replay accessible for 90 days.
  • Waters Corporation is a global leader in analytical instruments, separations technologies, and software.

The big picture

Waters' participation in the J.P. Morgan Healthcare Conference underscores the company's commitment to investor relations and its position within the critical analytical instruments sector. The conference itself is a significant gathering, attracting substantial assets under management and influencing investment decisions across the healthcare industry. Waters' presentation provides a valuable opportunity to communicate its strategic direction and address investor concerns regarding the company's long-term outlook.

What we're watching

Growth Strategy
How Waters articulates its growth strategy within the evolving landscape of biopharmaceutical development and quality control will be a key indicator of future performance.
Competitive Landscape
The presentation's commentary on the competitive environment and Waters' differentiation will reveal insights into the company's ability to maintain market share.
Investment Focus
The degree to which Waters emphasizes specific areas of investment, such as software or emerging technologies, will signal strategic priorities and potential shifts in resource allocation.
CID: 194